Up­dat­ed: Mer­ck Q2 earn­ings pro­pelled by Keytru­da, Gar­dasil sales, but ex­pects 's­low­er' growth for HPV vac­cine

Mer­ck tout­ed bil­lion-dol­lar sales growth for its can­cer drug Keytru­da and HPV vac­cine Gar­dasil this quar­ter, and has high ex­pec­ta­tions for both as reg­u­la­to­ry bod­ies …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER